Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2018

Feb 22, 2018

29777_dirs_2018-02-21_fc62b719-a1c8-4d18-a43e-d404951699fa.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2018-02-16

Reporting Person: LANE ANDREW H (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-02-20 Common shares without par value F 605 $60.17 Disposed 22294 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-02-16 Option (right to buy) $59.94 A 182935 Acquired 2028-02-15 Common shares (182935) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common shares without par value 1031 Indirect

Footnotes

F1: Includes shares acquired pursuant to a dividend reinvestment feature.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 16, 2018.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,979 on 02/16/2019, 60,978 on 02/16/2020, and 60,978 on 02/16/2021.